Tactile Systems Technology (TCMD) & Cryolife (CRY) Financial Contrast

Tactile Systems Technology (NASDAQ: TCMD) and Cryolife (NYSE:CRY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Insider & Institutional Ownership

92.0% of Tactile Systems Technology shares are owned by institutional investors. Comparatively, 67.6% of Cryolife shares are owned by institutional investors. 8.7% of Tactile Systems Technology shares are owned by company insiders. Comparatively, 4.0% of Cryolife shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Tactile Systems Technology and Cryolife, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tactile Systems Technology 1 2 3 0 2.33
Cryolife 0 0 3 0 3.00

Tactile Systems Technology currently has a consensus price target of $47.88, suggesting a potential downside of 12.59%. Cryolife has a consensus price target of $25.83, suggesting a potential downside of 10.61%. Given Cryolife’s stronger consensus rating and higher possible upside, analysts plainly believe Cryolife is more favorable than Tactile Systems Technology.

Earnings & Valuation

This table compares Tactile Systems Technology and Cryolife’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tactile Systems Technology $109.28 million 9.06 $5.85 million $0.21 260.81
Cryolife $189.70 million 5.58 $3.70 million $0.40 72.25

Tactile Systems Technology has higher earnings, but lower revenue than Cryolife. Cryolife is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tactile Systems Technology and Cryolife’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tactile Systems Technology 6.29% 7.86% 6.56%
Cryolife -1.15% 4.55% 2.50%

Volatility and Risk

Tactile Systems Technology has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Cryolife has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Summary

Tactile Systems Technology beats Cryolife on 9 of the 13 factors compared between the two stocks.

About Tactile Systems Technology

Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices for the treatment of chronic diseases in the United States. The company offers proprietary Flexitouch system, an at-home solution for lymphedema patients; and ACTitouch system, a home-based solution for chronic venous insufficiency patients. It also provides Entré System, a basic pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was founded in 1995 and is headquartered in Minneapolis, Minnesota.

About Cryolife

CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft systems for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G is a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply